Updated time: 2022-10-28 10:32:00
12A-1060912
TW I695839、US 11066412 B2、JP 7093410、EP3710005
The present invention relates to new hybrid molecules, which possess dual mechanism of action (VEGFR inhibition and DNA alkylation) and have a broad antitumor spectrum. Remarkably, it revealed that some compounds significantly suppressed the cell growth of small cell lung cancer SCLC H526 in xenograft models; more efficacious than cisplatin and vatalanib. The investigation indicates that the newly invented hybrids may have high potential of clinical application especially for cancer chemotherapy.
- The newly invented hybrids possess dual mechanism of action: VEGFR inhibition and DNA alkylation.
- Our investigation revealed that these hybrids have a broad antitumor spectrum.
- We demonstrated that some compounds significantly suppressed the cell growth of small cell lung cancer SCLC H520 in xenograft models with higher efficacy than cisplatin and vatalanib, but less toxicity to animals.
- Using as chemotherapeutic agent for treating colorectal cancer, non-small cell lung cancer, small cell lung cancer and pancreatic cancer.
Te-Chang Lee
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Novel antitumor compounds with anti-angiogenesis and DNA bifunctional alkylation -- synthetic methods and their use as cancer therapeutic agents